<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Boltz, Kathy</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Paz-Ares, Luis</style></author><author><style face="normal" font="default" size="100%">Novello, Silvia</style></author><author><style face="normal" font="default" size="100%">Goss, Glendwood D.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">ARCHER 1009 Subset Analysis and LUX-8 Lung: Erlotinib Compared With Dacomitinib or Afatinib</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-05-19 09:31:56</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">5-6</style></pages><abstract><style  face="normal" font="default" size="100%">The subgroup of patients with the EGFR-activating mutation in exon 19 or 21 appeared to have a favorable trend for dacomitinib vs erlotinib in progression-free survival. Afatinib was favored over erlotinib for second-line treatment of advanced squamous cell carcinoma in terms of progression-free survival, overall response rate, and disease control rate.</style></abstract><number><style face="normal" font="default" size="100%">8</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>